NCT04549467View on ClinicalTrials.gov

Efficacy of Dolutegravir Plus Lamivudine in HIV-1-infected Treatment-naïve Adults Without a Baseline Genotyping Test

PHASE4CompletedINTERVENTIONAL

Enrollment

244

Participants

Timeline

Start Date

November 17, 2020

Primary Completion Date

September 30, 2023

Study Completion Date

September 30, 2023

Conditions

HivHIV-1-infection

Interventions

DRUG

Lamivudine 300 MG

Experimental arm

DRUG

Emtricitabine / Tenofovir Disoproxil Pill

Active Comparator

Trial Locations (1)

1405

Fundacion IDEAA, Buenos Aires

Sponsors

Collaborators (1)

ViiV Healthcare

All Listed Sponsors

collaborator

ViiV Healthcare

INDUSTRY

lead

Fundacion IDEAA

OTHER